← Leaderboards
William McKinnon
Tulane University Of Louisiana
$49,515
Attributed
$49,515
Total exposure
16
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $15.3K · FY2005–06$20K$15K$10K$5K$0
'05
'06
Funding mix
By agency
NIH$49,515 · 16
By mechanism
M01$49,515 · 16
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Ellen L Zakris$642,522
- Patricia S Braly$22,399
- Eugene A Woltering$73,643
- Alan Marshall Miller$44,720
- Pui Chun Cheng$48,251
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectClinical ResearchCombination ChemotherapyNeoplasm /Cancer ChemotherapyBreast NeoplasmsDoxorubicinCyclophosphamideFemalePaclitaxelWomen'S HealthTamoxifenDrug Adverse EffectDrug Screening /EvaluationAntineoplasticsClinical Trial Phase IiiCombination Cancer TherapyPatient Oriented ResearchMethotrexateHuman MortalityOctreotideBreast Neoplasm /Cancer DiagnosisCervix NeoplasmsPreoperative State
Grant awards (23)
CHEMOTHERAPY REGIMENS IN WOMEN WITH NODE-POSITIVE BREAST CANCER$8,743
M01 · FY2006 · RR · contact PI
TRIAL TO COMPARE ADJUVANT ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOTERE$1,749
M01 · FY2006 · RR · contact PI
THERAPY TREATMENTS OF PATIENTS WITH OPERABLE CARCINOMA OF THE RECTUM$1,554
M01 · FY2006 · RR · contact PI
TRIAL COMPARING ADJUVANT CLODRONATE THERAPY VERSUS PLACEBO IN BREAST CANCER$1,166
M01 · FY2006 · RR · contact PI
TRIAL COMPARING SAFETY AND EFFICACY OF AC-T TO AC-T+H IN NODE-POSITIVE BREAST CA$1,166
M01 · FY2006 · RR · contact PI
TRIAL COMPARING PREOPERATIVE DOXORUBICIN AND CYCLOPHOSPHAMIDE TO PREOPERATIVE AC$972
M01 · FY2006 · RR · contact PI
TRIAL TO COMPARE ADJUVANT ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOTERE$6,508
M01 · FY2005 · RR
TRIAL COMPARING ADJUVANT CLODRONATE THERAPY VERSUS PLACEBO IN BREAST CANCER$3,254
M01 · FY2005 · RR
TRIAL COMPARING PREOPERATIVE DOXORUBICIN AND CYCLOPHOSPHAMIDE TO PREOPERATIVE AC$2,958
M01 · FY2005 · RR
TRIAL COMPARING SAFETY AND EFFICACY OF AC-T TO AC-T+H IN NODE-POSITIVE BREAST CA$591
M01 · FY2005 · RR
Trial Comparing Adjuvant Clodronate Therapy Vs Placebo$9,897
M01 · FY2004 · RR
Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere$7,776
M01 · FY2004 · RR
Trial Comparing Safety and Efficacy of AC-T to AC-T+H$3,181
M01 · FY2004 · RR
ADRIAMYCIN, CYCLOPHOSPHAMIDE, TAXOTERE IN BREAST CANCER$0
M01 · FY2001 · RR
SWOG 9717:EVALUATION OF INTRAVENOUSLY ADMINISTERED TIRAPAZAMINE + CIS$0
M01 · FY2001 · RR
NSABP B 27:PREOPERATIVE DOXORUBICIN &AC TO PREOPERATIVE AC FOLLOWED$0
M01 · FY2001 · RR
OCTREOTIDE/TAMOXIFEN IN BREAST CANCER$0
M01 · FY2001 · RR
NSABP B 23--SHORT INTENSIVE AC W/WO TAMOXIFEN W/ CONVENTIONAL CMF$0
M01 · FY2001 · RR
NSABP B 27:PREOPERATIVE DOXORUBICIN &AC TO PREOPERATIVE AC FOLLOWED$0
M01 · FY2000 · RR
OCTREOTIDE/TAMOXIFEN IN BREAST CANCER$0
M01 · FY2000 · RR
ADRIAMYCIN, CYCLOPHOSPHAMIDE, TAXOTERE IN BREAST CANCER$0
M01 · FY2000 · RR
SWOG 9717:EVALUATION OF INTRAVENOUSLY ADMINISTERED TIRAPAZAMINE + CIS$0
M01 · FY2000 · RR
NSABP B 23--SHORT INTENSIVE AC W/WO TAMOXIFEN W/ CONVENTIONAL CMF$0
M01 · FY2000 · RR